dc.creator | Garrido-Maraver, Juan | es |
dc.creator | Cordero, Mario D. | es |
dc.creator | Oropesa-Ávila, Manuel | es |
dc.creator | Fernández Vega, Alejandro | es |
dc.creator | Mata, Mario de la | es |
dc.creator | Delgado Pavón, Ana | es |
dc.creator | Miguel Rodríguez, Manuel de | es |
dc.creator | Sánchez-Alcázar, José Antonio | es |
dc.date.accessioned | 2023-02-08T13:32:18Z | |
dc.date.available | 2023-02-08T13:32:18Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Garrido-Maraver, J., Cordero, M.D., Oropesa-Ávila, M., Fernández Vega, A., Mata, M.d.l., Delgado Pavón, A.,...,Sánchez-Alcázar, J.A. (2014). Coenzyme Q(10) Therapy. Molecular Syndromology, 5 (3-4), 187-197. https://doi.org/10.1159/000360101. | |
dc.identifier.issn | 1661-8769 | es |
dc.identifier.issn | 1661-8777 (online) | es |
dc.identifier.uri | https://hdl.handle.net/11441/142548 | |
dc.description.abstract | For a number of years, coenzyme Q 10 (CoQ 10 ) was known for
its key role in mitochondrial bioenergetics; later studies
demonstrated its presence in other subcellular fractions and
in blood plasma, and extensively investigated its antioxidant
role. These 2 functions constitute the basis for supporting
the clinical use of CoQ 10 . Also, at the inner mitochondrial
membrane level, CoQ 10 is recognized as an obligatory cofactor
for the function of uncoupling proteins and a modulator
of the mitochondrial transition pore. Furthermore, recent
data indicate that CoQ 10 affects the expression of genes involved
in human cell signaling, metabolism and transport,
and some of the effects of CoQ 10 supplementation may be
due to this property. CoQ 10 deficiencies are due to autosomal
recessive mutations, mitochondrial diseases, aging-related
oxidative stress and carcinogenesis processes, and also
statin treatment. Many neurodegenerative disorders, diabetes,
cancer, and muscular and cardiovascular diseases have
been associated with low CoQ 10 levels as well as different
ataxias and encephalomyopathies. CoQ 10 treatment does
not cause serious adverse effects in humans and new formuhave been developed that increase CoQ 10 absorption
and tissue distribution. Oral administration of CoQ 10 is a frequent
antioxidant strategy in many diseases that may provide
a significant symptomatic benefit. | es |
dc.format | application/pdf | es |
dc.format.extent | 11 p. | es |
dc.language.iso | eng | es |
dc.publisher | KARGER | es |
dc.relation.ispartof | Molecular Syndromology, 5 (3-4), 187-197. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Clinical indications | es |
dc.subject | Coenzyme Q 10 | es |
dc.subject | Coenzyme Q 10 -related compounds | es |
dc.subject | Pharmacokinetics | es |
dc.title | Coenzyme Q(10) Therapy | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica | es |
dc.relation.projectID | FIS PI10/00543 | es |
dc.relation.projectID | FIS EC08/00076 | es |
dc.relation.projectID | SAS 111242 | es |
dc.relation.publisherversion | https://www.karger.com/Article/FullText/360101 | es |
dc.identifier.doi | 10.1159/000360101 | es |
dc.journaltitle | Molecular Syndromology | es |
dc.publication.volumen | 5 | es |
dc.publication.issue | 3-4 | es |
dc.publication.initialPage | 187 | es |
dc.publication.endPage | 197 | es |
dc.contributor.funder | Ministerio de Sanidad. España | es |
dc.contributor.funder | Servicio Andaluz de Salud. Junta de Andalucía | es |